Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors | Zendy

Motoo Nomura | Zendy; Ryosuke Nagatomo | Zendy; Keitaro Doi | Zendy; Juko Shimizu | Zendy; Kiichiro Baba | Zendy; Tomoki Saito | Zendy; Shigemi Matsumoto | Zendy; Kōichi Inoue | Zendy; Manabu Muto | Zendy

Open Access

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors

Author(s) -

Motoo Nomura,

Ryosuke Nagatomo,

Keitaro Doi,

Juko Shimizu,

Kiichiro Baba,

Tomoki Saito,

Shigemi Matsumoto,

Kōichi Inoue,

Manabu Muto

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.2895

Subject(s) - pembrolizumab , nivolumab , medicine , oncology , colorectal cancer , cancer , biomarker , tumor microenvironment , gastroenterology , response evaluation criteria in solid tumors , immune checkpoint , immune system , immunotherapy , immunology , clinical trial , biology , phases of clinical research , biochemistry

Key Points Question Are short-chain fatty acids associated with clinical outcomes in patients with solid cancer tumors treated with programmed cell death 1 inhibitors? Findings In this cohort study of 52 patients with solid tumors, high concentrations of fecal acetic acid, propionic acid, butyric acid, and valeric acid were significantly associated with longer progression-free survival. Meaning The findings suggest that fecal short-chain fatty acid concentrations may be a potential biomarker to identify patients with solid tumors who could benefit from treatment with programmed cell death 1 inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research